Uploaded June 2026 | Updated September 2026, 2 hours ago
Current therapies for inflammatory bowel disease (IBD) primarily focus on suppressing inflammation. But what if we could repair one of the underlying drivers of disease itself?
Hear from Amy Lightner, MD, as she discusses what we know and don't know about the current state of IBD treatments, and the research being done in developing CLF065, a potential first-in-class regenerative medicine designed to restore epithelial barrier function—the protective intestinal lining that regulates what passes from the gut into the body.
#ibd #education
https://www.scripps.edu/
Current therapies for inflammatory bowel disease (IBD) primarily focus on suppressing inflammation. But what if we could repair one of the underlying drivers of disease itself?
Hear from Amy Lightner, MD, as she discusses what we know and don't know about the current state of IBD treatments, and the research being done in developing CLF065, a potential first-in-class regenerative medicine designed to restore epithelial barrier function—the protective intestinal lining that regulates what passes from the gut into the body.
#ibd #education
https://www.scripps.edu/
